Država: Združene države Amerike
Jezik: angleščina
Source: NLM (National Library of Medicine)
TAMOXIFEN CITRATE (UNII: 7FRV7310N6) (TAMOXIFEN - UNII:094ZI81Y45)
KAISER FOUNDATION HOSPITALS
TAMOXIFEN CITRATE
TAMOXIFEN 10 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
TAMOXIFEN CITRATE- TAMOXIFEN CITRATE TABLET, FILM COATED KAISER FOUNDATION HOSPITALS ---------- TAMOXIFEN CITRATE TABLETS USP, 10 MG AND 20 MG (BASE) RX ONLY WARNING For Women With Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer Serious and life-threatening events associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence rates for these events were estimated from the NSABP P-1 trial (see CLINICAL PHARMACOLOGY, CLINICAL STUDIES, _REDUCTION IN BREAST CANCER INCIDENCE IN_ _HIGH RISK WOMEN_). UTERINE MALIGNANCIES CONSIST OF BOTH ENDOMETRIAL ADENOCARCINOMA (INCIDENCE RATE PER 1,000 WOMEN-YEARS OF 2.20 FOR TAMOXIFEN VS. 0.71 FOR PLACEBO) AND UTERINE SARCOMA (INCIDENCE RATE PER 1,000 WOMEN-YEARS OF 0.17 FOR TAMOXIFEN VS. 0.4 FOR PLACEBO) . FOR STROKE, THE INCIDENCE RATE PER 1,000 WOMEN-YEARS WAS 1.43 FOR TAMOXIFEN VS. 1.00 FOR PLACEBO . FOR PULMONARY EMBOLISM, THE INCIDENCE RATE PER 1,000 WOMEN-YEARS WAS 0.75 FOR TAMOXIFEN VERSUS 0.25 FOR PLACEBO . Some of the strokes, pulmonary emboli, and uterine malignancies were fatal. Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen to reduce their risk of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer. Updated long-term follow-up data (median length of follow-up is 6.9 years) from NSABP P-1 study. See WARNINGS, EFFECTS ON THE UTERUS-ENDOMETRIAL CANCER AND UTERINE SARCOMA. See TABLE 3 under CLINICAL PHARMACOLOGY, CLINICAL STUDIES. DESCRIPTION Tamoxifen citrate tablets USP, a nonsteroidal antiestrogen, are for oral administration. Each tablet contains 10 mg or 20 mg tamoxifen (equivalent to 15.2 mg or 30.4 mg, respectively, of tamoxifen citrate). Each tablet contains the following inactive ingredients: croscarmellose sodium, hyp Preberite celoten dokument